Effect of Osvalin and Piascladine on the treatment of knee osteoarthritis

Comparison of the efficacy of osvalin, piascladine and placebo in the improvement of pain in patients with knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180316039112N2

Enrollment

Registered

2019-08-05

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Arthrosis, unspecified

Interventions

Intervention 1: Intervention group I: Osvalin, the Shafatab Drug company produces in the form of a syrup. It prescript in a 5 ml daily. Intervention 2: Intervention group II: Piascledine, a 300 mg her

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with knee osteoarthritis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Measuring the pain at the beginning of the study (before the intervention) and 4, 8 and 12 weeks after starting the drug. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayeb Ramim

Iran University of Medical Sciences

tayebramim@yahoo.com+98 21 6651 5001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026